Enantia at Synthesis in Drug Discovery and Development

Enantia at Synthesis in Drug Discovery and Development

News

 

Home > News > Synthesis in Drug Discovery and Development Symposium

Merry Christmas and prosperous 2021!

Enantia is a speaker sponsor for the symposium

March 18th, 2021

Enantia is a speaker sponsor for the “Synthesis in Drug Discovery and Development” symposium which will be held by the Royal Society of Chemistry on the 22nd and 23rd of March.

This event will focus in innovative synthesis facilitating candidate discovery and overcoming the challenges of their scale up. These activities are carried out by Enantia in its Medicinal Chemistry and Process Chemistry departments respectively.

If you are interested in the chemical development of your candidates to optimize their activity, selectivity or toxicologic profile (among other properties) contact us to know more about our offer in Hit finding, H2L and LO programs.

Once a candidate is selected to be moved forward in the drug discovery process, one of Enantia’s main activities is the development of scalable routes of synthesis according to our clients’ requirements for a suitable scale up.

Contact us if you would like more information about any of our services.

Season’s greetings 2020

Season’s greetings 2020

News

 

Enantia's logo featuring the CIR logo with the french flag as background

Merry Christmas and prosperous 2021!

December 14th, 2020

We would like to wish a happy holiday to everyone who has placed their trust in Enantia during this year marked by the Covid-19 pandemic.

Thank you to all our customers, suppliers and employees, whose hard work has been essential in such a challenging year.

We wish you a safe and merry Christmas and a happy and prosperous 2021.

 

Enantia supports an environmental-friendly paper-free holiday season.

Enantia has been granted the Crédit d’Impôt Recherche (CIR) accreditation

Enantia has been granted the Crédit d’Impôt Recherche (CIR) accreditation

News

 

Home > News > Enantia has been granted CIR accreditation
Enantia's logo featuring the CIR logo with the french flag as background

Enantia has been granted the Crédit d’Impôt Recherche (CIR)
accreditation

November 10th, 2020

The French Ministry of Higher Education, Research and Innovation has granted Enantia with the Crédit d’Impôt Recherche (CIR) for the years 2020, 2021 and 2022.

The Crédit d’Impôt Recherche is a measure to support the research and development activities of French companies that have expenses in research and experimental development, who can benefit from the CIR by deducting them from their taxes under certain conditions.

This is great news for our French customers, especially those with a strong R&D activity like pharmaceutical companies, biotech, CDMOs and CMOs, that can now benefit from our CIR accreditation in all our services, which include medicinal chemistry, chemical development, solid state development and solid form analysis.

You can check our CIR accreditation here.

New Lead Optimisation paper in collaboration with Esteve

New Lead Optimisation paper in collaboration with Esteve

News

 

Home > News > New Lead Optimisation paper in collaboration with Esteve Pharmaceuticals

BarcelonaScienceParks20thanniversary

New Lead Optimisation paper in collaboration with Esteve Pharmaceuticals

October 26th, 2020

The Journal of Medicinal Chemistry has recently reported the results obtained in our Lead Optimisation collaboration with Esteve Pharmaceuticals, aimed at the identification of novel dual ligands of the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR), as part of Esteve’s R&D activities to develop new, potent and safer analgesics.
The chemistry work was developed by Enantia’s Medicinal Chemistry team, led by Dr. Marina Virgili, in collaboration with Esteve Pharmaceuticals. Previous investigations carried out at Enantia established a suitable Lead, comprised of a spirocyclic morpholino-piperidine core identified using rational drug design strategies. Subsequent Lead Optimization has led to the discovery of EST73502, a clinical candidate undergoing Phase I clinical trials. The compound showed promising results in animal models with potent analgesic efficacy and improved safety compared to oxycodone.

Enantia offers a wide portfolio of drug discovery services for pharmaceutical and biotech companies, including the design and synthesis of new scaffolds and libraries of small molecules with potential biological activity, covering Hit finding, Hit-to-Lead and Lead Optimization programs. Additionally, Enantia can collaborate with Structure-Activity Relationship (SAR) and Drug Metabolism and Pharmacokinetics (DMPK) data analysis. Enantia has a long track record of collaborative research projects with the pharmaceutical industry, leading to more than 20 patent applications related to medicinal chemistry.
Besides the most common MedChem activities, Enantia can also contribute to the early stages of the drug development by preparing cold labelled compounds and metabolites of the candidates. Additionally, for later phases of development, our Solid State department counts with extensive expertise in identifying the best solid form of the candidate to be further developed.

You can read the full paper here.

Process chemistry paper Angelini-Enantia

Process chemistry paper Angelini-Enantia

News

Home > News > New Process Chemistry paper in collaboration with Angelini Pharma

BarcelonaScienceParks20thanniversary

New Process Chemistry paper in collaboration with Angelini Pharma

A new paper has been published on the process chemistry work that Enantia and italian Angelini Pharma have done together.

Within this collaboration, a new robust and scalable synthetic route to obtain calcium acamprosate has been developed. The selective precipitation of calcium acamprosate as an easily filterable solid with 74–77% yield was achieved by the one-pot nucleophilic opening of 1,3-propanesultone with potassium acetamide, following by cation exchange with calcium ion at controlled pH.

In comparison with other procedures described in the literature and used previously, the newly developed and optimized methodology gives rise to a remarkably more efficient and direct synthesis of calcium acamprosate, avoiding the use of toxic chemicals and multistep synthesis.

This is a perfect example of how our process chemistry team can support our customers in designing and optimizing new routes of synthesis, leading to procedures that can be easily scaled up and used later at industrial scale. Furthermore, this type of projects can be complemented at Enantia by performing the carry-over of the impurities, and the characterization thereof.

 

You can read the full paper here.

Enantia at Future Cannabis Strategies Europe 2020

Enantia at Future Cannabis Strategies Europe 2020

News

Home > News > Enantia at Future Cannabis Strategies Europe 2020

Enantiacelebratesits15thanniversary

Enantia at Future Cannabis Strategies Europe 2020

January 17th, 2019

Our CEO Dr. Joan Feixas will be attending the Future Cannabis Strategies Europe 2020, taking place in Royal Lancaster London on the 29th and 30th of January, 2020.

During the event, we will be discussing with key partners and customers about our Cannabinoids Cocrystal Platform, which enables the manufacturing of a wide range of cannabinoids, both from natural and synthetic origin.

As part of this platform, Enantia is already developing commercial batches of API grade cGMP Cannabidiol (CBD), along with minor cannabinoids such as Cannabidivarin (CBDV), Cannabigerol (CBG), Cannabichromene (CBC) and Cannabinol (CBN).

If you are interested in our very high-quality cannabinoids, or if you are looking for a cost-effective purification technology for your cannabis extracts, do not hesitate to contact us to organize a meeting.

New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

News

Home > News > New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

BarcelonaScienceParks20thanniversary

New Medicinal Chemistry paper in collaboration with Esteve Pharmaceuticals

The Journal of Medicinal Chemistry has recently published some of the results obtained in our Medicinal Chemistry collaboration with Esteve Pharmaceuticals, aimed at the identification of novel dual ligands of the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR), as part of Esteve’s RD activity to develop new, potent and safer analgesics.

The chemistry work, which was carried out by Enantia’s Medicinal Chemistry team led by Dr. Marina Virgili, started with the design of the spirocyclic morpholino-piperidine core using rational drug design strategies. The efficient synthetic approach developed, allowed then for the rapid preparation of analogues with diversification in several positions of the scaffold, rendering the promising Lead described in this paper. The subsequent Lead Optimization program led to the discovery of a clinical candidate, whose identification will be reported soon.

Enantia has a long track record in Medicinal Chemistry services to the pharmaceutical industry, with more than 20 patents related to this activity, which includes the design and synthesis of new scaffolds and libraries of small molecules with potential biological activity.

In addition to conventional MedChem activities such as Hit-to-Lead and Lead Optimization programs, Structure-Activity Relationship (SAR) and Drug Metabolism and Pharmacokinetics (DMPK) interpretation, Enantia can also collaborate in the early stages of the drug development process by preparing cold labelled compounds and metabolites of a given candidate, as well as by identifying its best solid form in our Solid State department.

You can read the full paper here.

Merry Christmas and prosperous 2020!

Merry Christmas and prosperous 2020!

News

Home > News > Season’s greetings 2019
merrychrismasenantia

Merry Christmas and prosperous 2020!

December 17th, 2019

Special greetings at Christmas time to express our sincere thanks to everyone that has placed their confidence and loyalty to Enantia and has made this successful year possible.

Thanks to all our customers, employees, and suppliers, we wish you merry Christmas and a happy and prosperous 2020!

 

Enantia supports an environmental-friendly paper-free holiday season.

Biofit 2019

Biofit 2019

News

Home > News > Enantia at Biofit 2018
EnantiaatBiofit2018

Enantia at Biofit 2019

December 13th, 2019

 

On December 10th and 11th Marseille hosted the 8th Biofit event for big pharma, biotech companies, CROs and public research institutes.

On this edition, Enantia was selected to participate in the Service pitch session, in which we presented our state-of-the-art cocrystallization technology that enables selective, scalable and affordable purification processes of substances in complex mixtures.

We had the chance to strength former collaborations and to foster new networks. Thanks to everyone who came along.

Enantia attended the 30th edition of the CPhI Worldwide 2019

Enantia attended the 30th edition of the CPhI Worldwide 2019

News

Home > News > Enantia attended the 30th edition of the CPhI Worldwide 2019

Enantia CPHI 2019

Enantia at the 30th edition of the CPhI Worldwide 2019

November 19th, 2019

Enantia attended the 30th edition of the CPhI Worldwide 2019 event that took place in Frankfurt (Germany) from the 5th to the 7th of November.

Thanks to everyone for the interesting meetings.

We had the chance to discuss not only our services in chemical discovery and development, but also our cannabinoids cocrystal platform and the minor cannabinoids that we offer (CBDV, CBG, CBC, CBN).

We hope to meet you all very soon.